682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation

• Yun Wang,
• Ran Reshef,
• Gavin MacBeath,
• Jim Murray,
• Debora Barton,
• Erica Buonomo,
• Shrikanta Chattopadhyay,
• Monzr Al Malki,
• Alla Keyzner,
• Hyung C Suh,
• Aasiya Matin,
• Nina Abelowitz

Affiliations

Yun Wang

4 Department of Pharmaceutical Economics and Policy, School of Pharmacy, Chapman University, Orange, California, USA

Ran Reshef

Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA

Gavin MacBeath

TScan Therapeutics, Waltham, MA, USA

Jim Murray

Royal College of Surgeons in Ireland, Dublin, Ireland

Debora Barton

3Carisma Therapeutics, Springfield, NJ, USA

Erica Buonomo

1TScan Therapeutics, Waltham, MA, USA

Shrikanta Chattopadhyay

1TScan Therapeutics, Waltham, MA, USA

Monzr Al Malki

1City of Hope, Duarte, CA, USA

Alla Keyzner

2Mount Sinai Hospital, New York, NY, USA

Hyung C Suh

3Hackensack University, Hackensack, NJ, USA

Aasiya Matin

4Karmanos Cancer Institute, Detroit, MI, USA

Nina Abelowitz

5TScan Therapeutics, Waltham, MA, USA